Asahi Kasei Life Science Corp. is a Japanese company focused on life sciences, with activities centered on biotechnology and pharmaceutical technologies. It develops and commercializes advanced modalities, including antibody-drug conjugate (ADC) platforms that enable precise control over drug-to-antibody ratios, attachment sites, and the use of single or dual payloads.
The company collaborates on innovations derived from carbohydrate and glycan research to improve molecular conformity, therapeutic predictability, and safety profiles while reducing off-target effects. It works with partners such as The Noguchi Institute to advance these technologies toward commercialization, potential sublicensing, and further joint research for medical applications.
Official website: asahi-kasei.com/company/business/lifescience
